

Tuberculosis (TB) Risk Assessment

Name _____ PSU ID # _____ Date: _____

Persons with any of the following are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented.

Recent close contact with someone with infectious TB disease	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Foreign-born from (or travel* to/in) a high-prevalence area (e.g., Africa, Asia, Eastern Europe, or Central or South America)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Fibrotic changes on prior chest x-ray suggesting inactive or past TB disease	<input type="checkbox"/> Yes	<input type="checkbox"/> No
HIV/AIDS	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Organ transplant recipient	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Immunosuppressed (equivalent of > 15 mg/day of prednisone for > 1 month or TNF- antagonist)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
History of illicit drug use	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Resident, employee, or volunteer in a high-risk congregate setting (e.g., correctional facilities, nursing homes, homeless shelters, hospitals, and other health care facilities)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Medical condition associated with increased risk of progressing to TB disease if infected [e.g., diabetes mellitus, silicosis, head, neck, or lung cancer, hematologic or reticuloendothelial disease such as Hodgkin's disease or leukemia, end stage renal disease, intestinal bypass or gastrectomy, chronic malabsorption syndrome, low body weight (i.e., 10% or more below ideal for the given population)]	<input type="checkbox"/> Yes	<input type="checkbox"/> No

*The significance of the travel exposure should be discussed with a health care provider and evaluated.

1. **Does the student have signs or symptoms of active tuberculosis disease?** Yes No

Signs and Symptoms: cough (especially if lasting for 3 weeks or longer) with or without sputum production, coughing up blood (hemoptysis), chest pain, loss of appetite, unexplained weight loss, night sweats, fever.

If No, proceed to 2 or 3. If Yes, proceed with additional evaluation to exclude active tuberculosis disease including tuberculin skin testing, chest x-ray, and sputum evaluation as indicated.

2. **Tuberculin Skin Test (TST)** (If patient has history of BCG vaccination, consider IGRA if possible.) (TST result should be recorded as actual millimeters (mm) if induration, transverse diameter; if no induration, write "0". The TST interpretation should be based on mm of induration as well as risk factors.)**

Date Given: ___/___/___ Date Read: ___/___/___
M D Y M D Y

Result: ___ mm of induration **Interpretation: positive negative

3. **Interferon Gamma Release Assay (IGRA)**

Date Obtained: ___/___/___ (specify method) QTF-G QFT-GIT Other: _____
M D Y

Result: Positive Negative Intermediate

4. **Chest x-ray: (Required if TST or IGRA is positive)**

Date of chest x-ray: ___/___/___ Result: normal abnormal
M D Y

****Interpretation Guidelines**

>5 mm is positive:	>10 mm is positive:	>15 mm is positive:
<ul style="list-style-type: none"> Recent close contacts of an individual with infectious TB Person with fibrotic changes on a prior chest x-ray consistent with past TB disease Organ transplant recipients Immunosuppressed persons: taking >15mg/d of prednisone for > 1 month; taking TNF - antagonist Person with HIV/AIDS 	<ul style="list-style-type: none"> Persons born in a high prevalence country or who resided in one for a significant* amount of time History of illicit drug use Mycobacteriology laboratory personnel History of resident, worker or volunteer in high-risk congregate settings Persons with the following clinical conditions; silicosis, diabetes mellitus, chronic renal failure, leukemias and lymphomas, head, neck or lung cancer, low body weight (>10% below ideal), gastrectomy or intestinal bypass, chronic malabsorption syndromes 	<ul style="list-style-type: none"> Persons with no known risk factors for TB disease

*The significance of the travel exposure should be discussed with a health care provider and evaluated.

Management of Positive TST or IGRA

- Infected with HIV
- Recently infected with *M. tuberculosis* (within the past 2 years)
- History of untreated or inadequately treated TB disease, including person with fibrotic changes on chest radiograph consistent with prior TB disease
- Receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation.
- Diagnosed with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck or lung
- Have had a gastrectomy or jejunioileal bypass
- Weigh less than 90% of their ideal body weight
- Cigarette smokers and persons who abuse drugs and/or alcohol

**Populations defined locally as having an increased incidence of disease due to *M. tuberculosis*, including medically underserved, low-income populations

_____ Student agrees to receive treatment
_____ Student declines treatment at this time

HEALTH CARE PROVIDER

Name _____ Signature _____
Address _____ Phone (_____) _____